Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy

摘要: Prostate cancer is the most commonly diagnosed in men and second leading cause of cancer-related deaths each year. Androgen deprivation therapy has been gold standard care for advanced or metastatic prostate decades. While this treatment strategy initially shows benefit, eventually tumors recur as castration-resistant which there are limited options with only modest survival benefit. Upregulation insulin-like growth factor receptor type I (IGF-IR) signaling axis shown to drive cells many studies. As IGF-IR blockades have developed, few tested preclinically even fewer entered clinical trials therapy. In review, we will update recent preclinical studies cancer. We also discuss challenges targeted therapies achieve benefit